Xue Bai

Mr. Xue Bai

Department of Radiation Oncology, Southern Medical University, Guangzhou, Guangdong, China

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
XBXue Bai
Xue Bai
ZGZe-Qin Guo
Ze-Qin Guo
YZYan-Pei Zhang
Yan-Pei Zhang
ZFZhen-Zhen Fan
Zhen-Zhen Fan
LLLi-Juan Liu
Li-Juan Liu
ZDZhong-Yi Dong
Zhong-Yi Dong
Liver kinase B1 (LKB1) mutation is prevalent and a driver of resistance to immune checkpoint blockade (ICB) therapy for lung adenocarcinoma. Here leveraging single cell RNA sequencing data, we demonstrate that trafficking and adhesion process of activated T cells are defected in genetically engineered Kras-driven mouse model with Lkb1 conditional knockout. LKB1 mutant cancer cells result in marked suppression of intercellular adhesion molecule-1 (ICAM1). Ectopic expression of Icam1 in Lkb1-deficient tumor increases homing and activation of adoptively transferred SIINFEKL-specific CD8+ T cells, reactivates tumor-effector cell interactions and re-sensitises tumors to ICB. Further discovery proves that CDK4/6 inhibitors upregulate ICAM1 transcription by inhibiting phosphorylation of retinoblastoma protein RB in LKB1 deficient cancer cells. Finally, a tailored combination strategy using CDK4/6 inhibitors and anti-PD-1 antibodies promotes ICAM1-triggered immune response in multiple Lkb1-deficient murine models. Our findings renovate that ICAM1 on tumor cells orchestrates anti-tumor immune response, especially for adaptive immunity.

15 August 2025 in Cell Reports Medicine
Verified
Journal Article
Open access
XSXiangyu Sun
Xiangyu Sun
XCXiaoting Cai
Xiaoting Cai
SLShangbiao Li
Shangbiao Li
RPRuozheng Pi
Ruozheng Pi
ZGZeqin Guo
Zeqin Guo
XBXue Bai
Xue Bai
Liver kinase B1 (LKB1)-deficient non-small cell lung cancers (NSCLCs) exhibit primary resistance to immune checkpoint inhibitors (ICIs). The redox imbalance inherent in these tumors may represent a potential therapeutic vulnerability. High-dose ascorbic acid (AA) could induce cell redox imbalance. Here, we uncover that LKB1 deficiency upregulates the transporter GLUT1, which enables the accumulation of AA, thereby exacerbating redox imbalance in NSCLC cells. This triggers pyroptosis in LKB1-deficient NSCLC cells via the H2O2/reactive oxygen species (ROS)-caspase-3-gasdermin-E (GSDME) axis. In pre-clinical models, high-dose AA reverses ICI resistance and remodels the immune microenvironment, characterized by T cell factor 1 (TCF1)+CD8+ T cell (progenitor-exhausted CD8+ T cell [Tpex]) infiltration. Pyroptosis-driven immunogenic cell death (ICD) promotes cross-presenting dendritic cell (DC) maturation, which drives Tpex proliferation. Crucially, in Batf3-/- mice lacking functional CD103+ DC populations, both Tpex expansion and therapeutic benefits are abrogated, confirming DC dependence. In addition, GSDME is validated as a gatekeeper of pyroptosis-driven antitumor immunity. This work provides a rationale for clinical trials combining ICI with high-dose AA.

31 May 2025 in Lung
Verified
Journal Article
Closed access
PDF file
YLYan Lin
Yan Lin
JCJiaqi Chen
Jiaqi Chen
JTJiale Tan
Jiale Tan
ZYZihang Yu
Zihang Yu
RPRuozheng Pi
Ruozheng Pi
XBXue Bai
Xue Bai

1 May 2022 in Journal of Biomaterials and Tissue Engineering
Verified
Journal Article
Closed access
JSJin Song
Jin Song
JCJiahan Chang
Jiahan Chang
XLXue Lin
Xue Lin
CFCibo Fan
Cibo Fan
LHLili Han
Lili Han
XBXue Bai
Xue Bai
Triple-negative breast cancer (TNBC) remains a threat to women’s life with a lack of targeted therapy. This study aimed to explore the role of PTEN derived from BMSCs in TNBC. We carried out a retrospective analysis of 65 TNBC patients and 30 healthy subjects from October 2016 to January 2021 with a 10-year follow up. PTEN expression in TNBC tissues and cells was determined by RTqPCR. Functional experiments were conducted to evaluate PTEN’s effect on TNBC cell biological behaviors using MTT assay and Transwell assay, as well as on PI3K-Akt-HIF-1α-VEGF signaling transduction. PTEN was up-regulated in TNBC tissues relative to healthy controls and it was negatively associated with the survival rate. In in vitro experiments, PTEN overexpression increased cell viability and invasion and knocking down of PTEN exerted opposite effect. The expression of PI3K was directly regulated by PTEN. Up-regulation of PTEN resulted in a decline in HIF-1α, Akt and VEGF expressions, which were elevated after knocking down of PTEN. In conclusion, PTEN derived from BMSCs promotes TNBC cell development through blocking PI3K-Akt-HIF-1α-VEGF signaling pathway, providing a new theoretical basis for targeted therapy of TNBC.

20 March 2009 in The Chinese-German Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
CLChen Lin
Chen Lin
XBXue Bai
Xue Bai
LYLijian Yang
Lijian Yang
SCShaohua Chen
Shaohua Chen
BSBalachandar Selvakumar
Balachandar Selvakumar
YLYangqiu Li
Yangqiu Li